Article info
PDFClinical and epidemiological research
Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor α and systemic immune activation
- Dr S M Wahl, Bldg 30, Room 320, 30 Convent Dr, MSC 4352, Oral Infection and Immunity Branch, NIDCR, NIH, Bethesda, MD 20892, USA; SMWahl{at}mail.nih.gov
Citation
Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor α and systemic immune activation
Publication history
- Accepted December 20, 2007
- First published January 15, 2008.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and European League Against Rheumatism